Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders : humoral and cellular immune response
© 2023. The Author(s)..
BACKGROUND: The impact of immunosuppressive therapies on the efficacy of vaccines to SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated response after COVID-19 mRNA vaccine in immunosuppressed patients and patients with common variable immunodeficiency disease (CVID).
PATIENTS: We enrolled 38 patients and 11 healthy sex- and age-matched controls (HC). Four patients were affected by CVID and 34 by chronic rheumatic diseases (RDs). All patients with RDs were treated by corticosteroid therapy and/or immunosuppressive treatment and/or biological drugs: 14 patients were treated with abatacept, 10 with rituximab, and 10 with tocilizumab.
METHODS: Total antibody titer to SARS-CoV-2 spike protein was assessed by electrochemiluminescence immunoassay, CD4 and CD4-CD8 T cell-mediated immune response was analyzed by interferon-γ (IFN-γ) release assay, the production of IFN-γ-inducible (CXCL9 and CXCL10) and innate-immunity chemokines (MCP-1, CXCL8, and CCL5) by cytometric bead array after stimulation with different spike peptides. The expression of CD40L, CD137, IL-2, IFN-γ, and IL-17 on CD4 and CD8 T cells, evaluating their activation status, after SARS-CoV-2 spike peptides stimulation, was analyzed by intracellular flow cytometry staining. Cluster analysis identified cluster 1, namely the "high immunosuppression" cluster, and cluster 2, namely the "low immunosuppression" cluster.
RESULTS: After the second dose of vaccine, only abatacept-treated patients, compared to HC, showed a reduced anti-spike antibody response (mean: 432 IU/ml ± 562 vs mean: 1479 IU/ml ± 1051: p = 0.0034), and an impaired T cell response, compared with HC. In particular, we found a significantly reduced release of IFN-γ from CD4 and CD4-CD8 stimulated T cells, compared with HC (p = 0.0016 and p = 0.0078, respectively), reduced production of CXCL10 and CXCL9 from stimulated CD4 (p = 0.0048 and p = 0.001) and CD4-CD8 T cells (p = 0.0079 and p = 0.0006). Multivariable General Linear Model analysis confirmed a relationship between abatacept exposure and impaired production of CXCL9, CXCL10, and IFN-γ from stimulated T cells. Cluster analysis confirms that cluster 1 (including abatacept and half of rituximab treated cases) showed a reduced IFN-γ response, as well as reduced monocyte-derived chemokines All groups of patients demonstrated the ability to generate specific CD4 T activated cells after spike proteins stimulation. After the third dose of vaccine, abatacept-treated patients acquired the ability to produce a strong antibody response, showing an anti-S titer significantly higher compared to that obtained after the second dose (p = 0.0047), and comparable with the anti-S titer of the other groups.
CONCLUSIONS: Patients treated with abatacept showed an impaired humoral immune response to two doses of COVID-19 vaccine. The third vaccine dose has been demonstrated to be useful to induce a more robust antibody response to balance an impaired T cell-mediated one. All patients, exposed to different immunosuppressive drugs, were able to produce specific CD4-activated T cells, after spike proteins stimulation.
TRIAL REGISTRATION: Local Ethical Committee NP4187.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
BMC medicine - 21(2023), 1 vom: 14. Juni, Seite 210 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Filippini, Federica [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 16.06.2023 Date Revised 18.06.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12916-023-02868-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM358184355 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM358184355 | ||
003 | DE-627 | ||
005 | 20231226074213.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12916-023-02868-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1193.xml |
035 | |a (DE-627)NLM358184355 | ||
035 | |a (NLM)37316832 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Filippini, Federica |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders |b humoral and cellular immune response |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 16.06.2023 | ||
500 | |a Date Revised 18.06.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a BACKGROUND: The impact of immunosuppressive therapies on the efficacy of vaccines to SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated response after COVID-19 mRNA vaccine in immunosuppressed patients and patients with common variable immunodeficiency disease (CVID) | ||
520 | |a PATIENTS: We enrolled 38 patients and 11 healthy sex- and age-matched controls (HC). Four patients were affected by CVID and 34 by chronic rheumatic diseases (RDs). All patients with RDs were treated by corticosteroid therapy and/or immunosuppressive treatment and/or biological drugs: 14 patients were treated with abatacept, 10 with rituximab, and 10 with tocilizumab | ||
520 | |a METHODS: Total antibody titer to SARS-CoV-2 spike protein was assessed by electrochemiluminescence immunoassay, CD4 and CD4-CD8 T cell-mediated immune response was analyzed by interferon-γ (IFN-γ) release assay, the production of IFN-γ-inducible (CXCL9 and CXCL10) and innate-immunity chemokines (MCP-1, CXCL8, and CCL5) by cytometric bead array after stimulation with different spike peptides. The expression of CD40L, CD137, IL-2, IFN-γ, and IL-17 on CD4 and CD8 T cells, evaluating their activation status, after SARS-CoV-2 spike peptides stimulation, was analyzed by intracellular flow cytometry staining. Cluster analysis identified cluster 1, namely the "high immunosuppression" cluster, and cluster 2, namely the "low immunosuppression" cluster | ||
520 | |a RESULTS: After the second dose of vaccine, only abatacept-treated patients, compared to HC, showed a reduced anti-spike antibody response (mean: 432 IU/ml ± 562 vs mean: 1479 IU/ml ± 1051: p = 0.0034), and an impaired T cell response, compared with HC. In particular, we found a significantly reduced release of IFN-γ from CD4 and CD4-CD8 stimulated T cells, compared with HC (p = 0.0016 and p = 0.0078, respectively), reduced production of CXCL10 and CXCL9 from stimulated CD4 (p = 0.0048 and p = 0.001) and CD4-CD8 T cells (p = 0.0079 and p = 0.0006). Multivariable General Linear Model analysis confirmed a relationship between abatacept exposure and impaired production of CXCL9, CXCL10, and IFN-γ from stimulated T cells. Cluster analysis confirms that cluster 1 (including abatacept and half of rituximab treated cases) showed a reduced IFN-γ response, as well as reduced monocyte-derived chemokines All groups of patients demonstrated the ability to generate specific CD4 T activated cells after spike proteins stimulation. After the third dose of vaccine, abatacept-treated patients acquired the ability to produce a strong antibody response, showing an anti-S titer significantly higher compared to that obtained after the second dose (p = 0.0047), and comparable with the anti-S titer of the other groups | ||
520 | |a CONCLUSIONS: Patients treated with abatacept showed an impaired humoral immune response to two doses of COVID-19 vaccine. The third vaccine dose has been demonstrated to be useful to induce a more robust antibody response to balance an impaired T cell-mediated one. All patients, exposed to different immunosuppressive drugs, were able to produce specific CD4-activated T cells, after spike proteins stimulation | ||
520 | |a TRIAL REGISTRATION: Local Ethical Committee NP4187 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Abatacept | |
650 | 4 | |a Autoimmune diseases | |
650 | 4 | |a COVID-19 vaccination | |
650 | 4 | |a Interferon-γ | |
650 | 4 | |a Rituximab | |
650 | 4 | |a T cell | |
650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
650 | 7 | |a Abatacept |2 NLM | |
650 | 7 | |a 7D0YB67S97 |2 NLM | |
650 | 7 | |a Rituximab |2 NLM | |
650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a RNA, Messenger |2 NLM | |
700 | 1 | |a Giacomelli, Mauro |e verfasserin |4 aut | |
700 | 1 | |a Bazzani, Chiara |e verfasserin |4 aut | |
700 | 1 | |a Fredi, Micaela |e verfasserin |4 aut | |
700 | 1 | |a Semeraro, Paolo |e verfasserin |4 aut | |
700 | 1 | |a Tomasi, Cesare |e verfasserin |4 aut | |
700 | 1 | |a Franceschini, Franco |e verfasserin |4 aut | |
700 | 1 | |a Caruso, Arnaldo |e verfasserin |4 aut | |
700 | 1 | |a Cavazzana, Ilaria |e verfasserin |4 aut | |
700 | 1 | |a Giagulli, Cinzia |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC medicine |d 2003 |g 21(2023), 1 vom: 14. Juni, Seite 210 |w (DE-627)NLM143503421 |x 1741-7015 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2023 |g number:1 |g day:14 |g month:06 |g pages:210 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12916-023-02868-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2023 |e 1 |b 14 |c 06 |h 210 |